Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 7/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.40 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL657294 | 0.78 | SYK (0.42) | BCL6NCOR2ROCK2ROCK1SYK | |
| SCHEMBL4007211 | 0.75 | KIF11 (0.52) | BCL6 | |
| SCHEMBL654379 | 0.75 | SYK (0.51) | BCL6NCOR2SYK | |
| SCHEMBL656336 | 0.73 | SYK (0.39) | BCL6NCOR2SYKKMT2A | |
| SCHEMBL656737 | 0.73 | SYK (0.55) | BCL6SYKKMT2A | |
| SCHEMBL1116414 | 0.73 | JAK2 (0.48) | BCL6NCOR2ROCK2ROCK1SYK | |
| SCHEMBL655039 | 0.73 | SYK (0.42) | BCL6NCOR2SYKKMT2A | |
| SCHEMBL655084 | 0.73 | BCL6 (0.46) | BCL6NCOR2ROCK2ROCK1SYK | |
| SCHEMBL15494923 | 0.72 | KDR (0.46) | KMT2A | |
| SCHEMBL655463 | 0.72 | AXL (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349859-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-01-08 | — | — | US | disclosed |
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | HUTCHISON MEDIPHARMA ENTERPRISES LIMETED (BS) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255172-A1 | N4-(2-methyl-1H-indol-5-yl)-N2-phenylpyrimidine-2,4-diamine; angiogenesis related disorder like cancer or age-related macular degeneration | CCND2, KDR, FLT4 | BCL6 2561/4885NCOR2 3340/4885ROCK2 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.